TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03115164

Intervention type: OTHER
Intervention: To study the characteristics of patients with DIA / DIG
Description: Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
Study: NCT00006242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-214662
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00598884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Self-Management for Prolonged Grief Symptoms
Description: The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Based Self-Management for Prolonged Grief Symptoms
Description: The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
Study: NCT03864016

Intervention type: DRUG
Group type: OTHER
Intervention: Adaptation of sufentanil doses according to the usual protocol
Description: At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjustment of sufentanil doses according to pupillometry
Description: At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
Study: NCT02197910

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)
Study: NCT05640505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School based Gratitude Interventions
Description: Three gratitude interventions including Count your blessings, Gratitude Letter and Loving Kindness Meditation were applied with modification focusing on school related experiences. For example, writing a gratitude letter to a teacher, mentor or coach who played a significant role in one's life then imagining on the same person during LKM exercise of imagery. There were 9 sessions with 3-4 exercises in each session.
Study: NCT00234000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
Study: NCT02184767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADASUVE®
Description: ADASUVE® 2.5, 5, or 10 mg
Study: NCT02354625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous human Schwann cells
Description: Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
Study: NCT04597931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: SC Romosozumab 210 mg/monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: IV Zoledronic acid 5 mg
Study: NCT01246804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir single dose
Description: single dose 400mg raltegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir single dose
Description: single dose 400mg raltegravir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ginkgo biloba multiple dose
Description: 15 days ginkgo biloba 120mg BID
Study: NCT02018965

Intervention type: DRUG
Group type: OTHER
Intervention: Niacin
Description: • Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study.
Study: NCT01230970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495
Description: 40mg tablet oral daily administration from Day 1 to Day 14.
Study: NCT04370561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF non-locking
Description: Open reduction and internal fixation using 1/3 tubular plate
Study: NCT04459858

Intervention type: OTHER
Intervention: data analysis
Description: Data is extracted from the existing medical records and from the Rotator Cuff Repair Database (RCR_USB). The GTA (determined as the angle between a line parallel to the humerus diaphysis passing through the humeral head center of rotation and a line connecting the upper border of the humeral head to the most superolateral edge of the greater tuberosity) is determined.
Study: NCT01259388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
Study: NCT04226365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Description: 10mg capsule Nortryptyline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg capsule Thick-It filler
Study: NCT00384982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cells implantation
Description: percutaneous BM-derived cell therapy
Study: NCT04370561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF locking
Description: Open reduction and internal fixation using active ankle polyaxial locking plate
Study: NCT02018965

Intervention type: DRUG
Group type: OTHER
Intervention: Niacin
Description: • Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Niacin
Description: • Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study.
Study: NCT00890851

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transurethral Needle Ablation (TUNA)
Description: Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
Study: NCT02197351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: White light biopsy
Description: Endoscopy with biopsies guided by high definition white light

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolled
Description: Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging Guided Biopsy
Description: Upper Endoscopy with biopsy guided by narrow and imaging
Study: NCT02543879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-1101
Description: FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
Study: NCT03935555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
Study: NCT01710735

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Insertion of acupuncture needle into a myofascial trigger point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Insertion of acupuncture needle into a myofascial trigger point.
Study: NCT01862835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Study: NCT02867774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine.
Study: NCT01452295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELAD (Extracorporeal Liver Assist System)
Description: ELAD (Extracorporeal Liver Assist System)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELAD (Extracorporeal Liver Assist System)
Description: ELAD (Extracorporeal Liver Assist System)
Study: NCT02817347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 2% + tazobactam 0.25%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 4% + tazobactam 0.5%
Study: NCT02125877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox dispersible tablet
Description: Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
Study: NCT02543879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-1101
Description: FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-1101
Description: FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT-1101
Description: FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered per site's standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered per site's standard of care
Study: NCT04605133

Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: Every patient is monitored with electrical impedance tomograpy before, during and after prone position.
Study: NCT04715958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound
Description: Undergo CEUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo unenhanced baseline ultrasound
Study: NCT01228734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study: NCT02125877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defearisox film-coated tablet
Description: Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
Study: NCT01228734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: FA 200 mg/m\^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: 5-FU as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
Study: NCT03128099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality social skills training
Description: Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
Study: NCT03283267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS)
Description: Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS)
Description: Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
Study: NCT04258319

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Procedure
Description: Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Procedure
Description: Ultrasound technique that uses a compression device integrated with ultrasound imaging to perform in vivo ramp-and-hold uniaxial creep-like test on upper extremity lymphedema (UEL) in vivo.
Study: NCT01767324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection to deltoid
Description: Deliver 0.5 milliliters of saline intradermally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection to forearm
Description: Deliver 0.5 milliliters of saline intradermally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection to thigh
Description: Deliver 0.5 milliliters of saline intradermally
Study: NCT02996487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02448368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170,10 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170,10 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 2.5 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 5 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 5 mg
Description: Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 10 mg
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Study: NCT02817347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin 8% + tazobactam 1.0%
Study: NCT03271047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Orally, twice daily.
Study: NCT02448368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170, 10 mg
Description: Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
Study: NCT03836885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg; Day 2: 20 mg; Day 3: 30 mg; Day 4: 40 mg; Day 5: 50 mg. Day 6 and thereafter patients will be dosed at 60 mg for a total of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral tablets. Patients randomized to the control arm will receive color, taste, shape and odour matched oral placebo. The number of tablets and the days taken is analogous to the intervention arm had they been randomized to the intervention arm.
Study: NCT01968824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial Plexus Nerve Block
Description: The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
Study: NCT02280759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Tannate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of an identical formulation, except active substance
Study: NCT03286907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online videos
Description: Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 \& 8.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online videos and MI
Description: Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, \& 8.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises